

in vivo

- International Journal of Experimental and Clinical Pathophysiology and Drug Research
- Published bimonthly by the International Institute of Anticancer Research
- Available online with Stanford University HighWire Press

ISSN (print): 0258-851X; ISSN (online): 1791-7549

General Policy

- IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the framework of comparative physiology and pathology. The special focus of the journal is the publication of works on: (a) experimental development and the application of new diagnostic procedures; (b) pharmacological and toxicological evaluation of new drugs and drug combinations; (c) development and characterization of models for biomedical research.
- One of the principal aims of IN VIVO is to provide for the prompt publication of accepted articles, generally within 1-2 months from final acceptance.
- IN VIVO supports: (a) the aims and the research program of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IIAR) (Kapandriti, Attiki, Greece) and (b) the organization of the INTERNATIONAL CONFERENCES OF ANTICANCER RESEARCH.

Editorial Office

International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. Tel and Fax: +30-22950-53389; e-mail: journals@iiar-anticancer.org

For more information about IN VIVO, IIAR and the conferences please visit the IIAR websites: www.iiar-anticancer.org and www.iv.iiarjournals.org

Selection of Recent Articles

Effect of Radiation and Repeated Sub-culturing on the Transforming Growth Factor- β 1 Signaling Pathway in FRTL-5 Cells. C.G. BURRELL, D.S. GRIDLEY, L.S. ORTLOFF, S.M. CHARLES, L.M. GREEN (*Loma Linda, CA; Winston-Salem, NC, USA*)

IL6 Plasma Concentrations in Patients with Sepsis Receiving SLED and Antibiotics: A Predictor for Survival. T.R. MCGUIRE, N.T. REARDON, K. BOGARD, T.J. PLUMB, C.J. BULTSMA, S.W. NISSEN, P.D. FULLER, K.M. OLSEN (*Omaha, NE; Ocala, FL, USA*)

Organ-specific Responses of Total Body Irradiated Doxycycline-inducible Manganese Superoxide Dismutase Tet/Tet Mice. B.H. RHIEU, A. SHINDE, M.W. EPPERLY, T. DIXON, H. WANG, R. CHAILLET, J.S. GREENBERGER (*Pittsburgh, PA, USA*)

Effect of GPIIb/IIIa Inhibition with Eptifibatid or Tirofiban on the Expression of Cellular Adhesion Molecules on Monocytes. S. SWOBODA, T. WALTER, S. LANG, H.-P. WENDEL, M.E. BEYER, E. GRIESEL, H.-M. HOFFMEISTER, J. GRUETTNER (*Heidelberg; Tuebingen; Kirchheim; Solingen, Germany*)

Tolerated Doses in Zebrafish of Cytochalasins and Jasplakinolide for Comparison with Tolerated Doses in Mice in the Evaluation of Pre-clinical Activity of Microfilament-directed Agents in Tumor Model Systems *In Vivo*. M. TRENDOWSKI, V. WONG, K. WELLINGTON, S. HATFIELD, T.P. FONDY (*Syracuse, NY, USA*)

A Novel Role of CYP2E1 in Human Megakaryocyte Development. Y. TANG, G. ZHANG, M. BAIRD, F. RACKE, W. ZHAO (*Columbus, OH; San Juan Capistrano, CA, USA*)

Efficacy and Side Effects of a Semi-individualized Chinese Herb Mixture "Tiáo Gēng Tāng" for Menopausal Syndrome in China. M. JIA, L. KLUWE, H.-C. LIU, Q.-J. TANG, L. LIU, Z.-Z. WANG, L.-X. TIAN, L. ZHAO, Y.-C. CHEN, R.E. FRIEDRICH, Z.-J. SUN, L.-W. XU (*Shanghai, PR China; Hamburg, Germany*)

Sex Hormones Differentially Modulate STAT3-dependent Antioxidant Responses during Oxidative Stress in Renal Proximal Tubule Cells. D.K. REED, I. ARANY (*Jackson, MS, USA*)

Effect of Melatonin on Human Nighttime Endotoxaemia: Randomized, Double-blinded, Cross-over Study. M. ALAMILI, K. BENDTZEN, J. LYKKESFELDT, J. ROSENBERG, I. GÖGENUR (*Køge; Copenhagen; Herlev, Denmark*)

The Success Rate in a Complicated Spatial Memory Test Is Determined by Age, Sex, Life History and Search Strategies in Cynomolgus Monkeys. H.S. DARUSMAN, O. KALLIOKOSKI, D. SAJUTHI, S.J. SCHAPIRO, A. GJEDDE, J. HAU (*Copenhagen; Aarhus, Denmark; Bogor, Indonesia; Bastrop, TX; Baltimore, MD, USA; Montréal, QC, Canada*)

No Changes in Cerebral Microcirculatory Parameters in Rat During Local Cortex Exposure to Microwaves. H. MASUDA, S. HIROTA, A. USHIYAMA, A. HIRATA, T. ARIMA, H. WATANABE, K. WAKE, S. WATANABE, M. TAKI, A. NAGAI, C. OHKUBO (*Tokyo; Saitama; Aichi, Japan*)

Improving the Bioavailability and Anticancer Effect of the PCA-1/ALKBH3 Inhibitor HUHS015 Using Sodium Salt. M. MABUCHI, T. SHIMIZU, M. UEDA, Y. SASAKAWA, S. NAKAO, Y. UEDA, A. KAWAMURA, K. TSUJIKAWA, A. TANAKA (*Kobe; Osaka; Suita; Kainan, Japan*)

CAG-repeats in Androgen Receptor Gene Relate with Plasma Androgens Levels in the Bouvier Des Flandres. H. L' EPLATTENIER, E. TESKE, F. VAN SLUIJS, J.A. MOL (*Utrecht, Netherlands*)

Bone Substitutes Enhance Osteogenic Differentiation of Mesenchymal Stem Cells in Three-dimensional Scaffolds. H. HANKEN, J. ALPERS, M. BÖBEL, M. WÖLTJE, P. HARTJEN, R.E. FRIEDRICH, O. JUNG, C. RENDENBACH, A. GRÖBE, M. HEILAND, A. AL-DAM, W. EICHHORN, R. SMEETS (*Hamburg; Aachen, Germany*)

FREE SPECIMEN COPIES OF IN VIVO ARE AVAILABLE ON REQUEST

Instructions to Authors 2015

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) *First page* including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "review", "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) *Abstract* not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) *Introduction*; (d) *Materials and Methods/Patients and Methods*; (e) *Results*; (f) *Discussion*; (g) *Acknowledgements*; (h) *References*. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, at the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Colour plates are charged.

Tables. Tables should be typed double-spaced on a separate page, numbered with Roman numerals and should include a short title.

References. Authors must assume responsibility for the accuracy of the references used. Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones* (O' Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973.

Nomenclature and Abbreviations. Nomenclature should follow that given in "Chemical Abstracts", "Index Medicus", "Merck Index", "IUPAC –IUB", "Bergey's Manual of Determinative Bacteriology", The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix "ISRCTN" and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

Ethical Policies and Standards. ANTICANCER RESEARCH agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your article twice.):

1. To submit your article online please visit: IIAR-Submissions (<http://www.iiar-anticancer.org/submissions/login.php>)
2. You can send your article via e-mail to journals@iiar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies to the following address:

John G. Delinasios
International Institute of Anticancer Research (IIAR)
Editorial Office of ANTICANCER RESEARCH,
IN VIVO, CANCER GENOMICS and PROTEOMICS.
1st km Kapandritiou-Kalamou Road
P.O. Box 22, GR-19014 Kapandriti, Attiki
GREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Requests should be addressed to the Editorial Office.

Copyright© 2015 - International Institute of Anticancer Research (J.G. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

CANCER GENOMICS & PROTEOMICS

www.cgp.iarjournals.org

Print ISSN (2004-2012): 1109-6535

Online ISSN: 1790-6245

VOL. 1 (2004) - VOL. 9 (2012) (print and online)
From VOL. 10 (2013) online – only and open access



International Online **Open Access** Journal

General Policy. CANCER GENOMICS & PROTEOMICS (CGP) welcomes submissions of original high quality articles and reviews on all aspects of the application of genomic and proteomic technologies to experimental and clinical cancer research. The journal's scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) anticancer drug design and drug development.

CGP will also accept abstracts and proceedings of scientific meetings for publication, following consideration and approval by the Editorial Board.

A main aim of CGP is to ensure the prompt and confidential review, and rapid publication of original works and reviews, generally within 1-3 months from submission or 1-2 months from acceptance.

CGP is published bimonthly by the **International Institute of Anticancer Research** and is available online with **Stanford University HighWire Press**. For more information please visit our website www.cgp.iarjournals.org.

Editorial Office

International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389. E-mail: journals@iiar-anticancer.org; IIAR websites: www.iiar-anticancer.org and www.iarjournals.org

A Selection of Recent Articles

The Metastasis Suppressor NME1 Regulates Expression of Genes Linked to Metastasis and Patient Outcome in Melanoma and Breast Carcinoma. J.R. MCCORKLE, M.K. LEONARD, S.D. KRANER, E.M. BLALOCK, D. MA, S.G. ZIMMER, D.M. KAETZEL (*Memphis, TN; Baltimore, MD; Lexington, KY; Iowa City, IA, USA*)

Profiling of Chromosomal Changes in Potentially Malignant and Malignant Oral Mucosal Lesions from South and South-East Asia Using Array-Comparative Genomic Hybridization. M.L.S. LUNDE, E. ROMAN, S. WARNAKULASURIYA, R. MEHROTRA, J. LARANNE, E.N. VASSTRAND, S.O. IBRAHIM (*Bergen, Norway; London, UK; Allahabad, India; Tampere, Finland*)

Expression of Claudins in Human Clear Cell Renal Cell Carcinoma. W. MEN, T.A. MARTIN, F. RUGE, N. ZHANG, P. DU, Y. YANG, W.G. JIANG (*Beijing, China; Cardiff, UK*)

TCR-MHC/Peptide Interaction: Prospects for New Anti-tumoral Agents. U.H. WEIDLE, G. GEORGES, G. TIEFENTHALER (*Penzberg, Germany*)

Modulation of Liver-Intestine Cadherin (Cadherin 17) Expression, ERK Phosphorylation and WNT Signaling in EPHB6 Receptor-expressing MDA-MB-231 Cells. L. BHUSHAN, N. TAVITIAN, D. DEY, Z. TUMUR, C. PARSA, R.P. KANDPAL (*Pomona, CA, USA*)

Phenome-Genome Association Studies of Pancreatic Cancer: New Targets for Therapy and Diagnosis. R. NARAYANAN (*Boca Raton, FL, USA*)

Usefulness of Nanofluidic Digital PCR Arrays to Quantify T790M Mutation in EGFR-mutant Lung Adenocarcinoma. K. ISOBE, Y. HATA, N. TOCHIGI, K. KABURAKI, H. KOBAYASHI, T. MAKINO, H. OTSUKA, F. ISHIDA, N. HIROTA, G. SANO, K. SUGINO, S. SAKAMOTO, Y. TAKAI, K. SHIBUYA, A. IYODA, S. HOMMA (*Tokyo, Japan*)

Quantitative Proteomics of Bronchoalveolar Lavage Fluid in Lung Adenocarcinoma. S.A. ALMATROODI, C.F. MCDONALD, A.L. COLLINS, I.A. DARBY, D.S. POUNIOTIS (*Bundoora; Heidelberg, VIC, Australia; Buraidah, Saudi Arabia*)

Metabolic profile of Triple-negative Breast Cancer in African-American Women Reveals Potential Biomarkers of Aggressive Disease. Y.M. KANAAN, B.P. SAMPEY, D. BEYENE, A.K. ESNAKULA, T.J. NAAB, L.J. RICKS-SANTI, S. DASI, A. DAY, K.W. BLACKMAN, W. FREDERICK, R.L. COPELAND, E. GABRIELSON, R.L. DEWITTY JR. (*Washington DC; Durham, NC; Cleveland, OH; Hampton, VA; Baltimore, MD, USA*)

Analysis of SHOX2 Methylation as an Aid to Cytology in Lung Cancer Diagnosis. P. ILSE, S. BIESTERFELD, N. POMJANSKI, C. WROBEL, M. SCHRAMM (*Düsseldorf, Germany*)

The Role of Apurinic/Apyrimidinic Endonuclease DNA Repair Gene in Endometriosis. C.-M. HSU, W.-S. CHANG, J.-J. HWANG, J.-Y. WANG, Y.-L. HSIAO, C.-W. TSAI, J.-C. LIU, T.-H. YING, D.-T. BAU (*Taichung; Taipei, Taiwan, ROC*)

Epigenetic Silencing of GNMT Gene in Pancreatic Adenocarcinoma. A. BOTEZATU, C. BLEOTU, A. NASTASE, G. ANTON, N. BACALBASA, D. DUDA, S.O. DIMA, I. POPESCU (*Bucharest, Romania; Charlestown, MA, USA*)

Subscription Order Form 2015

- Please enter a Subscription to ANTICANCER RESEARCH Volume 35 (2015).
Annual subscription rates (2015): Institutional, Euro 1,650.00 print or online; Personal, Euro 780.00 print or online;
Prices include rapid delivery and insurance.
2015 online subscriptions include free online access to vol. 24 (2004) - 34 (2014).
- Please send me the following previous volumes (1-34) at 50% discount on the above rates.
- Payment is enclosed. Please invoice.
Checks should be made payable to Delinasios G.J. & CO G.P. (Athens, Greece)
- Please send me information about the International Institute of Anticancer Research (IIAR).

Name and Address:

 Tel:
 Fax: e-mail:
 Signature:..... Date:.....

Please send this order to ANTICANCER RESEARCH, Subscription Office, IIAR, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. Tel & Fax: +30-22950-53389, e-mail: subscriptions@iiar-anticancer.org

Special 2015 Offers to Authors of ANTICANCER RESEARCH

(These offers are open to all authors of articles published in Anticancer Research from 1981-2015 on a basis of priority and availability. Effective from January to December 2015).

- **Included in Pubmed, Current Contents and all abstracting and indexing services**
- **Online with Stanford University HighWire Press**
- **Open access articles**



Your link to the essential information on cancer research published in the last 33 years.

- 1981-2014
- 34 volumes
- over 116,000 pages
- over 16,900 original articles
- 834 reviews
- over 75,200 authors
- Conference abstracts
- Special issues
- Book reviews
- Author-Subject Indexes

Please complete and send this order form to:
 ANTICANCER RESEARCH, International Institute of Anticancer Research,
 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece.

Special Subscription Order Form 2015

- I am one of the authors of the article published in Anticancer Research Vol....., pp., year
- Please enter my personal subscription to Anticancer Research 2015 (Volume 35) at the special Author's rate of Euro 390.00 (print or online).
- Please send me previous Volume No(s) at Euro 195.00 (print) per volume.
- Please enter my personal combined 2015 subscription to Anticancer Research (Volume 35) and IN VIVO (Volume 29) at Euro 560.00 (print or online).
- My payment is enclosed.
- Please send me an invoice.
Prices include rapid delivery and insurance. Checks should be made payable to Delinasios G.J. & CO G.P. (Athens, Greece).

Name and address:

 Tel-Fax:
 e-mail:
 Date and signature:

Treatment Outcome of Radiotherapy for Localized Primary Ocular Adnexal MALT Lymphoma – Prognostic Effect of the AJCC Tumor- Node-Metastasis Clinical Staging System. S. OHGA, K. NAKAMURA, Y. SHIOYAMA, T. SASAKI, T. YAMAGUCHI, T. YOSHITAKE, K. TERASHIMA, K. ASAI, K. MATSUMOTO, H. HONDA (<i>Fukuoka; Saga, Japan</i>)	3591
ABSTRACTS OF THE INTERNATIONAL SYMPOSIUM “BIOLOGIC EFFECTS OF LIGHT” 11-12 June, 2015 Schlossberg Hotel, <i>Homburg/Saar, Germany</i>	3599
ABSTRACTS OF THE 25th ANNUAL MEETING OF THE ITALIAN SOCIETY OF URO-ONCOLOGY (SIUrO) 21-23 June, 2015, <i>Rome, Italy</i>	3615
Errata	3741

Preoperative Prediction of Peritoneal Metastasis in Gastric Cancer as an Indicator for Neoadjuvant Treatment. M. OHI, K. MORI, Y. TOIYAMA, Y. MOHRI, M. OKIGAMI, H. YASUDA, S. SAIGUSA, K. TANAKA, Y. INOUE, M. KUSUNOKI (<i>Mie, Japan</i>)	3511
The Role of Quaternary Cytoreduction in Recurrent Epithelial Ovarian Cancer: A Single-center Experience. N. BACALBAŞA, I. BALESCU, S. DIMA, V. BRASOVEANU, I. POPESCU (<i>Bucharest, Romania</i>)	3519
Local Therapy Improvement of Outcome in a Patient with Recurrent Hepatocellular Carcinoma After Living Donor Liver Transplantation: A Case Report. M. SHIMOKAWA, S. ITOH, T. IKEGAMI, K. TAKEISHI, N. HARIMOTO, Y.-I. YAMASHITA, T. YOSHIZUMI, H. KAWANAKA, K. SHIRABE, Y. MAEHARA (<i>Fukuoka, Japan</i>).....	3525
Multi-center Randomized Phase II Study of Weekly Docetaxel <i>Versus</i> Weekly Docetaxel-plus-Oxaliplatin as a Second-line Chemotherapy for Patients with Advanced Gastric Cancer. J.Y. KIM, H.M. RYOO, S.H. BAE, B.W. KANG, Y.S. CHAE, S. YOON, J.H. BAEK, M.K KIM, K.H. LEE, S.A. LEE, H.S. SONG, J.G. KIM (<i>Daegu; Ulsan, Republic of Korea</i>)	3531
Evaluation of IL-2, IL-6, IL-8 and IL-10 in Malignant Melanoma Diagnostics. R. KUCERA, O. TOPOLCAN, I. TRESKOVA, J. KINKOROVA, J. WINDRICOVA, R. FUCHSOVA, S. SVOBODOVA, V. TRESKA, V. BABUSKA, J. NOVAK, J. SMEJKAL (<i>Prague, Czech Republic</i>)	3537
Hopelessness/Helplessness in Healthy Individuals and in Patients with Benign Breast Disease and Breast Cancer: A Prospective Case-control Study in Finland. M. ESKELINEN, R. KORHONEN, T. SELANDER, P. OLLONEN (<i>Kuopio, Finland</i>).....	3543
The Impact of Perioperative Allogeneic Blood Transfusion on Survival in Elderly Patients with Colorectal Cancer. M. KANEKO, S. SASAKI, K. ISHIMARU, E. TERAJ, H. NAKAYAMA, T. WATANABE (<i>Tokyo, Japan</i>)	3553
Cerebral Relapsing Meningioma: A Surgical Series with Lack of Reliability of Standard Parameters Establishing Prognosis. F. FOREST, V. YVOREL, F. VASSAL, B. TROMBERT, J.-M. DUMOLLARD, C. NUTI, M. PÉOC'H (<i>Saint Étienne, France</i>)	3559
Short-term Survival of Patients with Lung Metastases from Colorectal and Non-colorectal Cancer Who Underwent Pulmonary Metastasectomy. F. LUMACHI, F. MAZZA, A. DEL CONTE, G. LO RE, M. ERMANI, G.B. CHIARA, S.M.M. BASSO (<i>Padova; Pordenone, Italy</i>).....	3563
PSA Isoforms' Velocities for Early Diagnosis of Prostate Cancer. I. HEIDEGGER, H. KLOCKER, R. PICHLER, W. HORNINGER, J. BEKTIC (<i>Innsbruck, Austria</i>)	3567
Impact of Stereotactic Radiosurgery Dose on Control of Cerebral Metastases from Renal Cell Carcinoma. D. RADES, S. HUTTENLOCHER, N. GEBAUER, D. HORNUNG, N.T. TRANG, M.T. KHOA, S.E. SCHILD (<i>Lübeck; Hamburg, Germany; Hanoi, Vietnam; Scottsdale, AZ, USA</i>).....	3571
Frequent High Expression of Kita-Kyushu Lung Cancer Antigen-1 (KK-LC-1) in Gastric Cancer. A. SHIDA, N. FUTAWATARI, T. FUKUYAMA, Y. ICHIKI, Y. TAKAHASHI, Y. NISHI, N. KOBAYASHI, H. YAMAZAKI, M. WATANABE (<i>Kitamoto, Saitama; Kitakyushu, Fukuoka; Sagamiyara, Kanagawa, Japan</i>).....	3575
Significance of Lymphatic Invasion Combined with Size of Primary Tumor for Predicting Sentinel Lymph Node Metastasis in Patients with Breast Cancer. T. FUJII, R. YAJIMA, H. TATSUKI, T. SUTO, H. MORITA, S. TSUTSUMI, H. KUWANO (<i>Maebashi, Gunma, Japan</i>)	3581
New Approach to Complete Video-assisted Thoracoscopic Lobectomy in T2 and T3 Non-Small Cell Lung Cancer. M. KATO, H. ONISHI, K. FURUGAKI, S. YUNOTANI, K. MATSUMOTO, N. TSURUTA, K. NAKAMURA, M. KATANO (<i>Karatsu, Saga; Fukuoka, Japan</i>)	3585

AGO Score As a Predictor of Surgical Outcome at Secondary Cytoreduction in Patients with Ovarian Cancer. M.Z. MUALLEM, K. GASIMLI, R. RICHTER, J. ALMUHEIMID, S. NASSER, E.I. BRAICU, J. SEHOULI (<i>Berlin, Germany</i>)	3423
A Cohort Study Evaluating the Role of Surgery for Lung Metastases from Colorectal Cancer. F. SOCOLA, D.M. NGUYEN, R.E. OCHOA, C.M. ROCHA LIMA, P.J. HOSEIN (<i>Little Rock, AR; Miami, FL; Lexington, KY, USA</i>)	3431
Second Primary Malignancies in Mantle Cell Lymphoma: A U.S. Population-based Study. B.K. SHAH, A. KHANAL (<i>Lewiston, ID; Chicago, IL, USA</i>)	3437
Adjuvant Chemoradiation in Pancreatic Cancer: A Pooled Analysis in Elderly (≥ 75 years) Patients. G.-C. MATTIUCCI, M. FALCONI, R.G.P.M. VAN STIPHOUT, S. ALFIERI, F.A. CALVO, J.M. HERMAN, B.W. MAIDMENT III, R.C. MILLER, W.F. REGINE, M. RENI, N. SHARMA, S. PARTELLI, D. GENOVESI, M. BALDUCCI, F. DEODATO, V. VALENTINI, A.G. MORGANTI (<i>Rome; Verona; Milan; Ancona; Chieti; Campobasso, Italy; Maastricht, the Netherlands; Madrid, Spain; Baltimore, MD; Charlottesville, VA; Rochester, MN, USA</i>)	3441
Retrospective Analysis of Concurrent Chemoradiation with Triweekly Cisplatin plus 5-Fluorouracil Versus Weekly Cisplatin in Cervical Cancer. K. SONODA, H. YAHATA, A. ICHINOE, K. OKUGAWA, E. KANEKI, Y. KAWANO, H. KENJO, T. OHGAMI, H. YAGI, S. OHGA, K. ASAI, K. NAKAMURA, H. HONDA, K. KATO (<i>Fukuoka, Japan</i>)	3447
Bevacizumab with FOLFIRI or XELIRI in the First-line Therapy of Metastatic Colorectal Carcinoma: Results from Czech Observational Registry. I. KOCAKOVA, B. MELICHAR, I. KOCAK, Z. BORTLICEK, T. BÜCHLER, L. DUSEK, L. PETRUZELKA, M. KOHOUTEK, J. PRAUSOVÁ, J. FINEK, B. MOHELNIKOVA-DUCHONOVA, R. VYZULA (<i>Brno; Olomouc; Prague; Zlin; Plzen, Czech Republic</i>)	3455
Preoperative Leucocytosis, Thrombocytosis and Anemia as Potential Prognostic Factors in Non-metastatic Renal Cell Carcinoma. G.C. HUTTERER, D. KRIEGER, E. MRSIC, K. POHLMANN, A. BEZAN, T. STOJAKOVIC, K. PUMMER, R. ZIGEUNER, M. PICHLER (<i>Graz, Austria; Houston, TX, USA</i>)	3463
Non-menopausal Status, High Nuclear Grade, Tumor Size >30 mm and Positive Resection Margins Are Predictors of Residual Tumor After Lumpectomy for Ductal Carcinoma <i>In Situ</i> of the Breast. M. JOSTE, V. MENDES, S. TIXIER, C. PALPACUER, B. LAVIOLLE, J. LEVEQUE, L. OULDAMER (<i>Rennes; Tours; Angers, France</i>)	3471
Role of Pelvic and Para-aortic Lymph Node Metastases in Optimally Cytoreduced Advanced Ovarian Cancer. C. BACHMANN, R. BACHMANN, S.Y. BRUCKER, A. STAEBLER, F. FEND, D. WALLWIENER, E.-M. GRISCHKE (<i>Tübingen, Germany</i>)	3479
Serrated Adenoma of the Gallbladder: A Case Report. C.A. RUBIO (<i>Stockholm, Sweden</i>)	3485
Sentinel Node Navigation Surgery for Lower Rectal Cancer. H. KAWAHARA, K. WATANABE, H. ENOMOTO, M. TOMODA, T. AKIBA, K. YANAGA (<i>Chiba; Tokyo, Japan</i>)	3489
Prognostic Value of Total Lesion Glycolysis Measured by ^{18}F -FDG-PET/CT in Patients with Colorectal Cancer. S. OGAWA, M. ITABASHI, C. KONDO, M. MOMOSE, S. SAKAI, S. KAMEOKA (<i>Tokyo, Japan</i>)	3495
Telomere Length Abnormalities and Telomerase RNA Component Expression in Gastroenteropancreatic Neuroendocrine Tumors. H.S. KIM, H.S. LEE, K.H. NAM, J. CHOI, W.H. KIM (<i>Seoul; Gyeonggi-do; Busan, Republic of Korea</i>)	3501

Correlation of <i>HIWI</i> and <i>HILI</i> Expression with Cancer Stem Cell Markers in Colorectal Cancer. M. LITWIN, J. DUBIS, K. ARCZYŃSKA, A. PIOTROWSKA, A. FRYDLEWICZ, M. KARCZEWSKI, P. DZIĘGIEL, W. WITKIEWICZ (Wroclaw, Poland)	3317
Differential Genomic Damage in Different Tumor Lines Induced by Prodigiosin. J.C. LAPENDA LINS, M.E.B. DE MELO, S.C. DO NASCIMENTO, M.L. ADAM (Recife; Pernambuco, Brazil)	3325
Microarray Gene-expression Profiling Analysis Comparing PCNSL and Non-CNS Diffuse Large B-Cell Lymphoma. D.H. LIM, W.S. KIM, S.J. KIM, H.Y. YOO, Y.H. KO (Cheonan; Seoul, Republic of Korea)	3333
Characterization of Cells Cultured from Chylous Effusion from a Patient with Sporadic Lymphangioliomyomatosis. I. GRZEGOREK, E. ZUBA-SURMA, M. CHABOWSKI, D. JANCZAK, A. SZUBA, P. DZIEGIEL (Wroclaw; Krakow, Poland)	3341
Immunohistochemical Evaluation of Pulmonary Lymphangioliomyomatosis. I. GRZEGOREK, D. LENZE, M. CHABOWSKI, D. JANCZAK, M. SZOLKOWSKA, R. LANGFORT, A. SZUBA, P. DZIEGIEL (Wroclaw, Poland; Berlin, Germany)	3353
Characterization of α -, β - and p120-Catenin Expression in Feline Mammary Tissues and their Relation with E- and P-Cadherin. A.C. FIGUEIRA, C. GOMES, H. VILHENA, S. MIRANDA, J. CARVALHEIRA, A.J.F. DE MATOS, P. DIAS-PEREIRA, F. GÄRTNER (Coimbra; Porto; Águeda; Vila Real; Vairão, Portugal)	3361
Biochemical Action of New Complexes of Ruthenium with Quinolones as Potential Antitumor Agents. M.I. GRUIA, V. NEGOITA, M. VASILESCU, M. PANAIT, I. GRUIA, B.S. VELESCU, V. UIVAROSI (Bucharest, Romania)	3371
Circulating Cytokine Levels in Patients with Prostate Cancer: Effects of Neoadjuvant Hormonal Therapy and External-beam Radiotherapy. N. TANJI, T. KIKUGAWA, T. OCHI, S. TAGUCHI, H. SATO, T. SATO, T. SUGAHARA, H. HAMADA, S. ASAI, A. MATSUMOTO (Ehime, Japan)	3379
<i>Clinical Studies</i>	
Effective Treatment of Transmissible Venereal Tumors in Dogs with Vincristine and IL2. W. DEN OTTER, M. HACK, J.J.L. JACOBS, J.F.V. TAN, L. ROZENDAAL, R.J.A. VAN MOORSELAAR (Amsterdam; Gouda, the Netherlands; Rondeklip, Curacao)	3385
Cyclin E Expression Correlates with Cancer-specific Survival in Endometrial Endometrioid Adenocarcinoma. S. SANTALA, A. TALVENSAARI-MATTILA, Y. SOINI, M. SANTALA (Oulu; Kuopio, Finland)	3393
Effective Therapeutic Intervention and Comprehensive Genetic Analysis of mTOR Signaling in PEComa: A Case Report. F. WEEBER, M.J. KOUDIJS, M. HOOGSTRAAT, N.J.M. BESSELINK, S. VAN LIESHOUT, I.J. NIJMAN, E. CUPPEN, G.J. OFFERHAUS, E.E. VOEST (Amsterdam; Utrecht, the Netherlands)	3399
Atypical Paracaval Recurrence of Uterine Endometrial Stromal Sarcoma: A Case Report. N. BACALBAŞA, I. BALESCU (Bucharest, Romania)	3405
Liver Transplantation Followed by Pulmonary Resection Complicated with End-Stage Liver Cirrhosis: A Case Report. D. TANIGUCHI, N. HARIMOTO, K. TAKEISHI, S. ITOH, Y. YAMASHITA, T. IKEGAMI, T. YOSHIZUMI, H. KAWANAKA, K. SHIRABE, Y. MORODOMI, T. TAGAWA, T. OKAMOTO, Y. MAEHARA (Fukuoka, Japan)	3411
Duration of First-line Treatment with Molecular Targeted-Therapy Is a Prognostic Factor in Metastatic Renal Cell Carcinoma. K. UEDA, S. SUEKANE, K. NISHIHARA, N. OGASAWARA, H. KUROSE, S. HAYASHI, K. CHIKUI, S. SUYAMA, M. NAKIRI, M. MATSUO, T. IGAWA (Fukuoka, Japan)	3415

Reduced Expression of RECK Protein May Help Differentiate Cutaneous Malignant Melanoma from Melanocytic Nevus. L. ZHANG, Q. XIE, S.-J. SHAN, M.K. TABOR, J.M. JUNKINS-HOPKINS (<i>Nanchang; Tianjin, PR China; New York, NY, USA</i>)	3185
Combination Efficacy of <i>Astragalus membranaceus</i> and <i>Curcuma wenyujin</i> at Different Stages of Tumor Progression in an Imageable Orthotopic Nude Mouse Model of Metastatic Human Ovarian Cancer Expressing Red Fluorescent Protein. G. YIN, D. TANG, J. DAI, M. LIU, M. WU, Y. SUN, Z. YANG, R.M. HOFFMAN, L. LI, S. ZHANG, X. GUO (<i>Nanjing, Jiangsu, PR China; San Diego, CA, USA</i>).....	3193
MicroRNA-145 Promotes the Phenotype of Human Glioblastoma Cells Selected for Invasion. S. KOO, G. MARTIN, L.G. TOUSSAINT (<i>Bryan, TX, USA</i>)	3209
Inflammation-Related Tumor Progression in Murine Fibrosarcoma Exhibited Over-expression of Sex-determining Region Y-box 2 (Sox2) Compared to Parental Regressor Cells. Y. KURAMITSU, I. TANAKA, Y. WANG, F. OKADA, K. TOKUDA, T. KITAGAWA, J. AKADA, K. NAKAMURA (<i>Ube; Shunan, Yamaguchi; Yonago, Japan</i>)	3217
Gene Expression Profiling of MCF10A Breast Epithelial Cells Exposed to IOERT. L. MINAFRA, V. BRAVATA, G. RUSSO, G.I. FORTE, F.P. CAMMARATA, M. RIPAMONTI, G. CANDIANO, M. CERVELLO, A. GIALLONGO, G. PERCONTI, C. MESSA, M.C. GILARDI (<i>Cefalù; Palermo; Milan; Monza, Italy</i>)	3223
Induction of G ₁ Arrest by SB265610 Involves Cyclin D3 Downregulation and Suppression of CDK2 (Thr160) Phosphorylation. A.E. GODA, R.L. ERIKSON, J.-S. AHN, B.-Y. KIM (<i>Cheongwon, Republic of Korea; Cambridge, MA, USA; Tanta, Egypt</i>)	3235
Reversal of ABCB1-related Multidrug Resistance of Colonic Adenocarcinoma Cells by Phenothiazines. D. TAKÁCS, Á. CSONKA, Á. HORVÁTH, T. WINDT, M. GAJDÁCS, Z. RIEDL, G. HAJÓS, L. AMARAL, J. MOLNÁR, G. SPENGLER (<i>Budapest; Szeged, Hungary; Lisbon, Portugal</i>)	3245
Differential Gene Regulation in Fibroblasts in Co-culture with Keratinocytes and Head and Neck SCC Cells. M. HAKELIUS, D. SAIEPOUR, H. GÖRANSSON, K. RUBIN, B. GERDIN, D. NOWINSKI (<i>Uppsala, Sweden</i>).....	3253
ROCK I Has More Accurate Prognostic Value than MET in Predicting Patient Survival in Colorectal Cancer. J. LI, S.S. BHARADWAJ, G. GUZMAN, R. VISHNUHOTLA, S.C. GLOVER (<i>Gainesville, FL; Chicago, IL, USA</i>).....	3267
Cellular Vaccines Modified with Hyper IL6 or Hyper IL11 Combined with Docetaxel in an Orthotopic Prostate Cancer Model. J. MACKIEWICZ, U. KAZIMIERCZAK, M. KOTLARSKI, E. DONDAJEWSKA, A. KOZŁOWSKA, E. KWIATKOWSKA, A. NOWICKA-KOTLARSKA, H. DAMS-KOZŁOWSKA, P.J. WYSOCKI, A. MACKIEWICZ (<i>Poznan, Poland</i>).....	3275
Microarray Analysis Reveals Distinct Gene Set Profiles for Gastric and Intestinal Gastrointestinal Stromal Tumors. R. HARA, H. KIKUCHI, T. SETOGUCHI, S. MIYAZAKI, M. YAMAMOTO, Y. HIRAMATSU, K. KAMIYA, M. OHTA, S. BABA, H. KONNO (<i>Hamamatsu, Japan</i>)	3289
MCP1-Induced Epithelial–Mesenchymal Transition in Head and Neck Cancer by AKT Activation. C.-C. LEE, H.-C. HO, Y.-C. SU, M.-S. LEE, S.-K. HUNG, C.-H. LIN (<i>Chiayi; Hualian, Taiwan, ROC</i>).....	3299
Bortezomib Causes ER Stress-related Death of Acute Promyelocytic Leukemia Cells Through Excessive Accumulation of PML–RARA. M. TAKENOKUCHI, K. MIYAMOTO, K. SAIGO, T. TANIGUCHI (<i>Hyogo, Japan</i>)	3307